Table 2.
Use of hormone replacement therapy | Any
|
Without progestin
|
With progestin
|
|||||
---|---|---|---|---|---|---|---|---|
No of cases/ | Odds ratio* | No of cases/ controls | Odds ratio* | No of cases/ controls | Odds ratio* | |||
controls | (95% CI) | (95% CI) | (95% CI) | |||||
Never | 956/2073 | 1.00 (reference) | 956/2073 | 1.00 (reference) | 956/2073 | 1.00 (reference) | ||
Ever: | 120/456 | 0.58 (0.46 to 0.75) | 81/229 | 0.69 (0.52 to 0.93) | 56/274 | 0.46 (0.32 to 0.66) | ||
Current | 40/239 | 0.36 (0.24 to 0.53) | 16/62 | 0.48 (0.26 to 0.87) | 24/17 | 0.29 (0.17 to 0.48) | ||
Former | 80/217 | 0.76 (0.57 to 1.01) | 65/167 | 0.76 (0.56 to 1.04) | 32/9 | 0.71 (0.46 to 1.12) | ||
Per year of use: | ||||||||
Ever | 0.94 (0.91 to 0.97) | 0.96 (0.92 to 0.99) | 0.89 (0.84 to 0.94) | |||||
Current | 0.91 (0.87 to 0.95) | 0.94 (0.88 to 0.99) | 0.84 (0.76 to 0.92) | |||||
Former | 0.97 (0.93 to 1.02) | 0.98 (0.92 to 1.04) | 0.93 (0.85 to 1.02) |
Adjusted for age (50 to 54, 55 to 59, 60 to 64, 65 to 69, 70 to 74, 75 to 81 years) and the indication of hormone replacement therapy to prevent osteoporosis (yes/no).